Metabolon To Sponsor Study At Geisinger Medical Center With Quantose IR To Monitor Prediabetes Therapy

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C., June 23, 2014 (GLOBE NEWSWIRE) -- Metabolon, Inc., a global leader in metabolomics, announced today that it will sponsor a pilot study to evaluate its Quantose IRTM test as a monitor of glycemic control in people with prediabetes. The study, which will monitor prediabetic subjects using Quantose IR, hemoglobin A1c and fasting plasma glucose (FPG) results over a 12-week period, will be conducted by the Cardiovascular Center for Clinical Research at Geisinger Medical Center in Danville, PA. Study participants will be on a regimen of metformin, diet and exercise.

Help employers find you! Check out all the jobs and post your resume

MORE ON THIS TOPIC